In an exclusive interview, study author Dr. Karina Eterovic, R&D Director of Oncology Diagnostics at Eurofins Viracor BioPharma, discusses the complex interplay between clonal hematopoiesis and cancer genomics, in the context of precision of cancer diagnosis and treatment.
Germline sequencing provides crucial insights into clonal hematopoiesis mutations with the potential to improve cancer patient outcomes and new oncology therapy development